“ RYR plus conventional therapy ” exhibited significant lowering effects on serum total cholesterol ( TC ) , low-density lipoprotein cholesterol ( LDL-C ) , and CRP but exhibited no significant effect on systolic BP , diastolic BP , triglycerides ( TG ) , and high-density lipoprotein cholesterol ( HDL-C ) compared with “ placebo plus conventional therapy . ” “
RYR plus conventional therapy ” showed significant lowering effects on systolic BP , TC , LDL-C , and CRP but no effect on diastolic BP , TG , and HDL-C compared with “ placebo plus conventional therapy . ”
No significant difference in BP and lipid profile between “ RYR plus conventional therapy ” and “ statins plus conventional therapy ” was observed .
“ RYR plus statins ” appeared to be more effective in lowering BP , TC , TG , and LDL-C but without a significant difference in HDL-C compared to statins .
No serious adverse events were reported .
The results of this meta- analysis suggested some supportive but limited evidence regarding RYR for hypertension .
ABSTRACT Interest is increasing regarding the potential health effects of red yeast rice ( RYR ) consumption , which is described as a “ natural statin ” in China .
This review aims to evaluate the efficacy of RYR on blood pressure ( BP ) , lipid profile , and C-reactive protein ( CRP ) in treating  hypertension .
Xuezhikang, An Extract of Cholestin, Reduces Cardiovascular Events in Type 2 Diabetes Patients With Coronary Heart Disease: Subgroup Analysis of Patients With Type 2 Diabetes From China Coronary Secondary Prevention Study (CCSPS)
Lipid-lowering therapy has been proven to reduce macrovascular complications of type 2 diabetes .  Xuezhikang is an extract of cholestin and has a markedly modulating effect on lipids , but the effect of xuezhikang on reducing coronary events in diabetic patients with coronary heart disease ( CHD ) is less clear . A total of 591 diabetic patients with CHD were r and omized to the xuezhikang group ( n = 306 ) and the placebo group ( n = 285 ) . During the average 4 years of follow-up , there were 28 cases of CHD events ( 9.2 % ) in the xuezhikang group and 53 cases ( 18.6 % ) in the placebo group . Risk reduction for CHD events was 50.8 % ( P < 0.001 ) by xuezhikang treatment . Xuezhikang decreased the risk of non-fatal MI by 63.8 % , fatal MI by 58.5 % , CHD sudden death by 26.9 % , and other CHD death by 53.4 % . CHD death totaled to 21 cases in the xuezhikang group ( 6.9 % ) and 35 cases in the placebo group ( 12.3 % ) , indicating that xuezhikang significantly decreased the risk of CHD death by 44.1 % ( P < 0.05 ) . Seventy-two patients died from various causes , among which there were 27 patients in the xuezhikang group and 45 patients in the placebo group . The risk for all-cause death was 44.1 % lower in the xuezhikang group than in the placebo group ( P < 0.01 ) . This investigation demonstrates that xuezhikang therapy can be effective on reduction of cardiovascular events in diabetic patients with CHD with a reliable safety
“ RYR plus conventional therapy ” exhibited significant lowering effects on serum total cholesterol ( TC ) , low-density lipoprotein cholesterol ( LDL-C ) , and CRP but exhibited no significant effect on systolic BP , diastolic BP , triglycerides ( TG ) , and high-density lipoprotein cholesterol ( HDL-C ) compared with “ placebo plus conventional therapy . ” “
RYR plus conventional therapy ” showed significant lowering effects on systolic BP , TC , LDL-C , and CRP but no effect on diastolic BP , TG , and HDL-C compared with “ placebo plus conventional therapy . ”
No significant difference in BP and lipid profile between “ RYR plus conventional therapy ” and “ statins plus conventional therapy ” was observed .
“ RYR plus statins ” appeared to be more effective in lowering BP , TC , TG , and LDL-C but without a significant difference in HDL-C compared to statins .
No serious adverse events were reported .
The results of this meta- analysis suggested some supportive but limited evidence regarding RYR for hypertension .
ABSTRACT Interest is increasing regarding the potential health effects of red yeast rice ( RYR ) consumption , which is described as a “ natural statin ” in China .
This review aims to evaluate the efficacy of RYR on blood pressure ( BP ) , lipid profile , and C-reactive protein ( CRP ) in treating  hypertension .